摘要
Abstract
Objective:To investigate the efficacy of sacubitril valsartan combined with bisoprolol in patients with chronic heart failure(CHF).Method:A total of 100 patients with CHF admitted to Wudang Hospital Affiliated to Guizhou Medical University from April 2019 to April 2024 were enrolled and randomly divided into the observation group(bisoprolol+sacubitril valsartan)and the control group(bisoprolol)using a random number table method,with 50 cases in each group.Both groups were treated for 2 months.The clinical efficacy,remission time of clinical symptoms,cardiac function indexes[left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),N-terminal pro-brain natriuretic peptide(NT-proBNP),left ventricular ejection fraction(LVEF)],inflammatory factors[high-sensitivity C-reactive protein(Hs-CRP),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]and adverse reactions were compared between the two groups.Result:Compared with the control group,the total clinical effective rate was significantly higher and the recovery time of clinical symptoms was significantly shorter in the observation group,with statistically significant differences(P＜0.05).After treatment,the levels of NT-proBNP,LVESD,LVEDD,IL-8,Hs-CRP,TNF-α and IL-6 were significantly lower,while LVEF was significantly higher in the observation group than those in the control group,with statistically significant differences(P＜0.05).Conclusion:Sacubitril valsartan combined with bisoprolol can promote clinical symptom relief,reduce inflammation levels,improve cardiac function in CHF patients,with significant therapeutic effects and good safety.关键词
慢性心力衰竭/沙库巴曲缬沙坦/比索洛尔/临床疗效/不良反应/心功能Key words
Chronic heart failure/Sacubitril valsartan/Bisoprolol/Clinical efficacy/Adverse reactions/Cardiac function
